Trpv2 as a new therapeutic target to modulate blood brain barrier properties

The present invention relates to a method for modulating blood-brain barrier (BBB) in a subject comprising a step of administering said subject with a therapeutically effective amount of a modulator of transient receptor potential vanilloid-2 (TRPV2). For the first time, inventors have shown that TRPV2 is present in endothelial cells of BBB. More particularly, Inventor’s results show that cannabidiol (CBD), at extracellular concentrations close to those observed in plasma of patients treated by CBD, and induces proliferation, migration, tubulogenesis and TEER increase in human brain endothelial cells, suggesting TRPV2 as a potent target for modulating the human BBB.

Keywords: BBB dysfunction - TRPV2 agonist
Patent Application number: EP19305131.5

Reference:

BIO18544-T1

Business Developper
contact
Anne COCHI
Anne COCHI
Business Development Manager
Patent filling date: 04-02-2019

You might also be interested in